as 12-18-2024 1:30pm EST
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 78.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 47.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.19 - $13.00 | Next Earning Date: | 04-03-2025 |
| Revenue: | $122,000 | Revenue Growth: | -93.99% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ABP Breaking Stock News: Dive into ABP Ticker-Specific Updates for Smart Investing
The information presented on this page, "ABP Abpro Holdings Inc Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.